LON:CLIN Clinigen Group (CLIN) Share Price, News & Analysis → Your $200 account credit is about to expire (From MarketBeat) (Ad) Free CLIN Stock Alerts GBX 925 0.00 (0.00%) (As of 04/4/2022) Add Compare Share Share Today's Range 925▼ 92550-Day Range 925▼ 92552-Week Range 541.50▼ 948.05Volume539,375 shsAverage Volume1.83 million shsMarket Capitalization£1.23 billionP/E Ratio64.69Dividend Yield0.01%Price TargetN/A Stock AnalysisStock Analysis Get Clinigen Group alerts: Email Address Ad MarketBeatYour $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionStart Your Risk-Free Trial Here About Clinigen Group Stock (LON:CLIN)Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.Read More CLIN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLIN Stock News HeadlinesMarch 13, 2024 | bloomberg.comElliott Alumnus De La Riviere Joins Tech Entrepreneur’s FundFebruary 18, 2024 | finanznachrichten.deReal World Evidence Solutions Market Worth $4.5 Billion | MarketsandMarkets.March 28, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… September 12, 2023 | technews.tmcnet.comClinigen launches NaviGATE: an educational programme for rare disease patients and organisationsSeptember 8, 2023 | msn.comSMALL CAP MOVERS: Will Ergomed and Instem end up on the Nasdaq?August 10, 2023 | benzinga.comClinigen divests global rights to four cancer support therapies to CNX TherapeuticsMay 3, 2023 | marketwatch.comOral Mucositis Market Emerging Trends till 2031April 27, 2023 | marketwatch.comCompounding Pharmacies Market Size, Trends, Growth Status, Share, Research, and Forecast 2023 to 2031March 28, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 3, 2023 | markets.businessinsider.comSuccessful transaction: Adragos Pharma has officially taken over Clinigen's development unit, Lamda Laboratories near Athens, GreeceMarch 30, 2023 | marketwatch.comReal World Evidence Solutions Market 2023 Size and Forecast to 2031March 30, 2023 | marketwatch.com2023-2030 Jet Lag Treatment Market Size with Manufactures (Teva, Mylan, Nature’s Bounty)March 30, 2023 | markets.businessinsider.comEQS-News: PAION AG reports on fiscal year 2022March 28, 2023 | marketwatch.comOral Mucositis Drugs Market Growth and Forecast till 2030March 27, 2023 | marketwatch.comReal World Evidence Solutions Market Premium Research Report Forecast 2023 To 2029March 25, 2023 | marketwatch.comOral Mucositis Market Top Players and Forecast till 2031March 23, 2023 | marketwatch.comGlobal Jet Lag Treatment Market Size by Application (Hospital Pharmacies, Retail Pharmacies, Online) Forecast from 2023 to 2028March 23, 2023 | marketwatch.comAmifostine Market Growth and Forecast till 2031March 22, 2023 | marketwatch.comReport on Real World Evidence Solutions market tells us TODAY how this market will develop in the next 10 yearsMarch 21, 2023 | uk.finance.yahoo.comCompounding Pharmacies Global Market Report 2022: Featuring Avella Specialty Pharmacy, Central Admixture, PharMEDium, Rx3 Compounding & MoreMarch 15, 2023 | marketwatch.com2023-2028 Amifostine Market Growth and Size Analysis by Industry Experts | Latest Research ReportMarch 14, 2023 | marketwatch.comReal World Evidence Solutions Market 2023 | Global Industry Report Forecast 2029March 3, 2023 | marketwatch.comExploring the Human Papillomaviru Therapeutics Market: Progresses for Huge Profits during 2023-2028February 10, 2023 | marketwatch.comAmifostine Market to Grow Exponentially Due to Rising DemandJanuary 30, 2023 | marketwatch.comAmifostine Market Set to High Latest Developments, Growth Prospects 2023-2027 with Future Trends and Share AnalysisJanuary 29, 2023 | marketwatch.comOral Mucositis Drugs Market Research report forecast 2023 To 2028, Latest Industry News, Top Company Analysis, Research MethodologyJanuary 25, 2023 | marketwatch.comOral Mucositis Therapeutics Market Size, Share, Growth, Revenue, Demand, Future Potential, and Forecast from 2023 to 2028See More Headlines Receive CLIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clinigen Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/17/2020Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Delivery Sub-IndustryN/A Current SymbolLON:CLIN CUSIPN/A CIKN/A Webwww.clinigengroup.com Phone+44-1283-495010FaxN/AEmployees1,000Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio64.69 Forward P/E Ratio0.36 P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio90.77 Current Ratio1.89 Quick Ratio1.48 Sales & Book Value Annual Sales£565.60 million Price / Sales2.18 Cash FlowGBX 88.30 per share Price / Cash Flow10.48 Book ValueGBX 341.90 per share Price / Book2.71Miscellaneous Outstanding Shares133,367,000Free FloatN/AMarket Cap£1.23 billion OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Shaun Edward Chilton (Age 54)CEO & Exec. Director Comp: $662kRichard PalingInterim Chief Financial Officer & Group Financial ControllerMr. Sam HerbertChief Operating OfficerRob FoxVP of Investor Relations & Corp. Devel.Ms. Amanda MillerGen. Counsel & Company Sec.Mr. David BryantDirector of Corp. Devel.Jessica ArcherGlobal HR DirectorMr. Mark CorbettManaging Director of Global Access DivisionMr. Johannes Willemse (Age 54)Chief Commercial Officer Mr. Ivo Timmermans M.D. (Age 62)MBA, Chief Medial Officer More ExecutivesKey CompetitorsEMIS GroupLON:EMISGenusLON:GNSOxford Nanopore TechnologiesLON:ONTVectura GroupLON:VECSpire Healthcare GroupLON:SPIView All Competitors CLIN Stock Analysis - Frequently Asked Questions How have CLIN shares performed in 2024? Clinigen Group's stock was trading at GBX 925 at the beginning of 2024. Since then, CLIN shares have increased by 0.0% and is now trading at GBX 925. View the best growth stocks for 2024 here. How were Clinigen Group's earnings last quarter? Clinigen Group plc (LON:CLIN) announced its quarterly earnings results on Thursday, September, 17th. The company reported $65.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $63.50 by $2.10. Is Clinigen Group a good dividend stock? Clinigen Group (LON:CLIN) pays an annual dividend of GBX 0.08 per share and currently has a dividend yield of 0.82%. The dividend payout ratio is 0.53%. This payout ratio is at a healthy, sustainable level, below 75%. Read our dividend analysis for CLIN. What other stocks do shareholders of Clinigen Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clinigen Group investors own include Comerica (CMA), Honda Motor (HMC), Advanced Accelerator Applications (AAAP), Albemarle (ALB), First Hawaiian (FHB), Landec (LNDC), NII (NIHD), RTI International Metals (RTI), General Electric (GE) and NetApp (NTAP). How do I buy shares of Clinigen Group? Shares of CLIN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:CLIN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThe 3rd Revolution in WarfareWeiss RatingsIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill PublishingAI to Meet the Same Fate as EVs? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clinigen Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.